Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Short-term Investments (2020 - 2024)

Cytek Biosciences (CTKB) has disclosed Short-term Investments for 4 consecutive years, with $29000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Short-term Investments fell 91.24% year-over-year to $29000.0, compared with a TTM value of $29000.0 through Dec 2024, down 91.24%, and an annual FY2024 reading of $29000.0, down 91.24% over the prior year.
  • Short-term Investments was $29000.0 for Q4 2024 at Cytek Biosciences, down from $30816.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.9 million in Q1 2023 and bottomed at $29000.0 in Q4 2024.
  • Average Short-term Investments over 4 years is $940727.0, with a median of $365500.0 recorded in 2023.
  • Peak annual rise in Short-term Investments hit 86.29% in 2024, while the deepest fall reached 91.24% in 2024.
  • Year by year, Short-term Investments stood at $888000.0 in 2020, then skyrocketed by 226.46% to $2.9 million in 2022, then tumbled by 88.58% to $331000.0 in 2023, then tumbled by 91.24% to $29000.0 in 2024.
  • Business Quant data shows Short-term Investments for CTKB at $29000.0 in Q4 2024, $30816.0 in Q3 2024, and $30000.0 in Q2 2024.